Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Highly Accessed Opinion

Towards the clinical implementation of pharmacogenetics in bipolar disorder

Naji C Salloum12, Michael J McCarthy12, Susan G Leckband12 and John R Kelsoe123*

Author Affiliations

1 Department of Psychiatry (0603), University of California San Diego, La Jolla, CA 92093, USA

2 VA San Diego Healthcare System, 3350 La Jolla Village Drive, La Jolla, CA 92151, USA

3 Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA

For all author emails, please log on.

BMC Medicine 2014, 12:90  doi:10.1186/1741-7015-12-90

Published: 30 May 2014

Abstract

Background

Bipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide. Although effective treatments for BD exist, variability in outcomes leads to a large number of treatment failures, typically followed by a trial and error process of medication switches that can take years. Pharmacogenetic testing (PGT), by tailoring drug choice to an individual, may personalize and expedite treatment so as to identify more rapidly medications well suited to individual BD patients.

Discussion

A number of associations have been made in BD between medication response phenotypes and specific genetic markers. However, to date clinical adoption of PGT has been limited, often citing questions that must be answered before it can be widely utilized. These include: What are the requirements of supporting evidence? How large is a clinically relevant effect? What degree of specificity and sensitivity are required? Does a given marker influence decision making and have clinical utility? In many cases, the answers to these questions remain unknown, and ultimately, the question of whether PGT is valid and useful must be determined empirically. Towards this aim, we have reviewed the literature and selected drug-genotype associations with the strongest evidence for utility in BD.

Summary

Based upon these findings, we propose a preliminary panel for use in PGT, and a method by which the results of a PGT panel can be integrated for clinical interpretation. Finally, we argue that based on the sufficiency of accumulated evidence, PGT implementation studies are now warranted. We propose and discuss the design for a randomized clinical trial to test the use of PGT in the treatment of BD.

Keywords:
Bipolar Disorder; Pharmacogenomics; Lithium; Antidepressants; Antipsychotics